Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron

To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidas...

Full description

Saved in:
Bibliographic Details
Published inNephron (2015) Vol. 69; no. 4; p. 404
Main Authors Delmas-Beauvieux, M C, Combe, C, Peuchant, E, Carbonneau, M A, Dubourg, L, de Précigout, V, Aparicio, M, Clerc, M
Format Journal Article
LanguageEnglish
Published Switzerland 1995
Subjects
Online AccessGet more information

Cover

Loading…
Abstract To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidase, and catalase (Cat), (ii) RBC polyunsaturated fatty acids (PUFA) and (iii) malondialdehyde (MDA). Group 1 included 12 HD patients, group 2 had 7 HD patients with iron supplementation, group 3 comprised 12 HD patients with rHuEPO therapy and group 4 included 9 HD patients with both iron and rHuEPO therapies. No LPO was found in group 1 as regards MDA and PUFA levels. However, SOD and Cat activities were significantly elevated as compared to controls (p < 0.001). In the second group, a significant decrease in PUFA percentage was observed, particularly in 20:4(n-6) and 22:4(n-6) (the main ones involved in LPO) as compared to the other groups, whereas total MDA level was higher than that of the other groups. Similarly a decreased SOD activity was observed as compared to group 1 (p < 0.001), indicating its inactivation subsequent to an hyperproduction of reactive oxygen species through iron injection. In groups 3 and 4 no change was observed in MDA levels or PUFA percentages indicating no LPO. However, marked differences were observed in the enzymatic defense system. Particularly in group 3, SOD and Cat activities decreased when compared to group 1 (p < 0.001) whereas the association of erythropoietin and iron (group 4) increased the three enzymatic activities (p < 0.001).
AbstractList To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidase, and catalase (Cat), (ii) RBC polyunsaturated fatty acids (PUFA) and (iii) malondialdehyde (MDA). Group 1 included 12 HD patients, group 2 had 7 HD patients with iron supplementation, group 3 comprised 12 HD patients with rHuEPO therapy and group 4 included 9 HD patients with both iron and rHuEPO therapies. No LPO was found in group 1 as regards MDA and PUFA levels. However, SOD and Cat activities were significantly elevated as compared to controls (p < 0.001). In the second group, a significant decrease in PUFA percentage was observed, particularly in 20:4(n-6) and 22:4(n-6) (the main ones involved in LPO) as compared to the other groups, whereas total MDA level was higher than that of the other groups. Similarly a decreased SOD activity was observed as compared to group 1 (p < 0.001), indicating its inactivation subsequent to an hyperproduction of reactive oxygen species through iron injection. In groups 3 and 4 no change was observed in MDA levels or PUFA percentages indicating no LPO. However, marked differences were observed in the enzymatic defense system. Particularly in group 3, SOD and Cat activities decreased when compared to group 1 (p < 0.001) whereas the association of erythropoietin and iron (group 4) increased the three enzymatic activities (p < 0.001).
Author Dubourg, L
Peuchant, E
Clerc, M
de Précigout, V
Carbonneau, M A
Aparicio, M
Delmas-Beauvieux, M C
Combe, C
Author_xml – sequence: 1
  givenname: M C
  surname: Delmas-Beauvieux
  fullname: Delmas-Beauvieux, M C
  organization: Laboratoire de Biochimie Médicale A, Université de Bordeaux II, France
– sequence: 2
  givenname: C
  surname: Combe
  fullname: Combe, C
– sequence: 3
  givenname: E
  surname: Peuchant
  fullname: Peuchant, E
– sequence: 4
  givenname: M A
  surname: Carbonneau
  fullname: Carbonneau, M A
– sequence: 5
  givenname: L
  surname: Dubourg
  fullname: Dubourg, L
– sequence: 6
  givenname: V
  surname: de Précigout
  fullname: de Précigout, V
– sequence: 7
  givenname: M
  surname: Aparicio
  fullname: Aparicio, M
– sequence: 8
  givenname: M
  surname: Clerc
  fullname: Clerc, M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/7777104$$D View this record in MEDLINE/PubMed
BookMark eNot0MtKxDAUBuAgI2MdZ-EDCHmBak6S3pYyjBcYcKPrIW1SG0mTkKZqtz65gZmzOfDznX9xrtHKOqsQugVyD1A0D4QQqOsCyAXKKGVFzqAuVyiDsiR5DQVcoe00fSVGGbCG8TVaV2mA8Az97b-FmUXUzmLX46Akbo1zEnfKGGy0d14F96vliWiLBzU6qYVZpmR9ipWNE5Zz0PYTq7DEITjvtIrJxkEF4Rc8zd4bNSaZblzA1kX8o-OAdXD2Bl32wkxqe94b9PG0f9-95Ie359fd4yHvaMVi3tKOyULUDfSd6EQvRQWiragCBbzikvGqbuqybFkFHW8bVgieJCWsEwR6Rjfo7tTr53ZU8uiDHkVYjudf0H88wGYi
CitedBy_id crossref_primary_10_1111_j_1440_1797_2002_tb00506_x
crossref_primary_10_1016_j_hoc_2013_11_002
crossref_primary_10_1016_S0891_5849_96_00282_1
crossref_primary_10_1016_j_cbi_2009_06_007
crossref_primary_10_1038_sj_ki_5002482
crossref_primary_10_1046_j_1523_1755_2000_00443_x
crossref_primary_10_1016_j_foodchem_2015_06_088
crossref_primary_10_1038_ki_1997_466
crossref_primary_10_1111_j_1525_1594_2004_29011_x
crossref_primary_10_1080_10715769800300011
crossref_primary_10_3390_nu10101353
crossref_primary_10_1046_j_1440_1797_7_s_2_x
crossref_primary_10_1203_01_PDR_0000146032_98120_43
crossref_primary_10_14302_issn_2574_4488_jna_19_3112
crossref_primary_10_1081_JDI_120002663
crossref_primary_10_1016_j_nut_2012_06_002
crossref_primary_10_1111_j_1492_7535_2005_01116_x
crossref_primary_10_1046_j_1525_139X_1999_99028_x
crossref_primary_10_1074_jbc_274_27_18916
crossref_primary_10_1152_ajprenal_00200_2006
crossref_primary_10_1097_00002480_200009000_00023
crossref_primary_10_1111_trf_15257
crossref_primary_10_1111_j_1440_1797_2004_00262_x
crossref_primary_10_1177_039139889902200203
crossref_primary_10_1186_1471_2431_5_29
crossref_primary_10_1111_j_1542_4758_2007_00144_x
crossref_primary_10_1046_j_1523_1755_2003_00741_x
crossref_primary_10_1093_ajcn_64_5_757
crossref_primary_10_1046_j_1525_1594_2003_07170_x
crossref_primary_10_1097_00002480_200109000_00024
crossref_primary_10_1016_j_fct_2012_01_042
crossref_primary_10_1016_S0006_2952_99_00277_4
crossref_primary_10_1046_j_1525_1594_1999_06328_x
crossref_primary_10_1093_ndt_16_2_335
crossref_primary_10_1155_2010_978710
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1159/000188510
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 2235-3186
ExternalDocumentID 7777104
Genre Clinical Trial
Controlled Clinical Trial
Journal Article
GroupedDBID 0R~
30W
327
4.4
53G
7X7
88E
8AO
8FI
8FJ
ABUWG
ACGFS
ADBBV
AENEX
AFKRA
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AZPMC
BENPR
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
CYUIP
EBS
ECM
EIF
EJD
EMB
EMOBN
F5P
FYUFA
HMCUK
HZ~
KUZGX
M1P
NPM
O1H
O9-
PQQKQ
PROAC
PSQYO
RKO
RXVBD
S0X
SV3
UKHRP
ID FETCH-LOGICAL-c273t-b2c3d5a891fcacafda71ab72e1e1474d34789866b371c4b935a4fca203ca01f32
ISSN 1660-8151
IngestDate Fri May 24 00:04:13 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c273t-b2c3d5a891fcacafda71ab72e1e1474d34789866b371c4b935a4fca203ca01f32
PMID 7777104
ParticipantIDs pubmed_primary_7777104
PublicationCentury 1900
PublicationDate 1995-00-00
PublicationDateYYYYMMDD 1995-01-01
PublicationDate_xml – year: 1995
  text: 1995-00-00
PublicationDecade 1990
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Nephron (2015)
PublicationTitleAlternate Nephron
PublicationYear 1995
SSID ssj0002313934
Score 1.6461267
Snippet To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated...
SourceID pubmed
SourceType Index Database
StartPage 404
SubjectTerms Adult
Aged
Anemia - blood
Anemia - drug therapy
Anemia - etiology
Catalase - blood
Erythrocytes - drug effects
Erythrocytes - metabolism
Erythropoietin - therapeutic use
Fatty Acids, Unsaturated - blood
Female
Glutathione Peroxidase - blood
Humans
Iron - administration & dosage
Lipid Peroxidation - drug effects
Male
Malondialdehyde - blood
Middle Aged
Renal Dialysis - adverse effects
Superoxide Dismutase - blood
Uremia - blood
Uremia - complications
Uremia - therapy
Title Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron
URI https://www.ncbi.nlm.nih.gov/pubmed/7777104
Volume 69
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Rb9MwELY6ENJe0BBMMDbkB96iQBw7cfI4YGhCouJhk_Y22Y4jitakahOJ8rh_s3-5O9tt0zIkIA9RZDtW6vtyvlzvviPkLewCGnblKlayymMB70SsS2VjpBZJy1Qj4QdGW4zz80vx5Sq7Go3uBlFLfaffmV8P5pX8j1ShDeSKWbL_INn1pNAA1yBfOIOE4fxXMj5bU3WjzYeR5C4OPUJvfHQzmbXIAv5z4ssmoWfju522mCmyXMDYQKm6WKUq2vnSF02YYBp05DOzltEC6346JyLc086jpu289xYT5Ia27djOkGkXbVbY77OBj-GTvZmqRfzBqh624d7td183_lnQSdpueWy_2R4zkrvtVAk11xiWo3p__-nGY-EzwNceC69k8zyJCxaIZq1rAysF_5EPtNhBM_siLgGBYqBmhS9Z_Lv6z0ofL8kKsCST4RiQ3GzqcCDhYNsTPNi5w8MdevbInixQlY6DW-iH4wwCQ9pHMKx-W2Cxgid6v36effIkzLLzEeOMmYsD8jR8hdBTD6lnZGSb5-R2Ayfa1hTgRB2cKMKJ7sKJTho6hBNdwYl6ONFtONEAJzqEE23nFOBEEU4U4fSCXH4-u_h4HocSHbEBu7eLdWp4lamiZLVRRtWVkkxpmVpmmZCi4kIWZZHnmktmhC55pgSMTBNuVMJqnh6SR03b2JdIHgCLlCJ9ZKLAssoU56awqeamrGsr81fk0C_Z9czzsFyHtTz6U8drsr-B3zF5XMNrb0_Ahuz0Gye_e403c98
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+red+blood+cell+lipoperoxidation+in+hemodialysed+patients+during+erythropoietin+therapy+supplemented+or+not+with+iron&rft.jtitle=Nephron+%282015%29&rft.au=Delmas-Beauvieux%2C+M+C&rft.au=Combe%2C+C&rft.au=Peuchant%2C+E&rft.au=Carbonneau%2C+M+A&rft.date=1995-01-01&rft.issn=1660-8151&rft.eissn=2235-3186&rft.volume=69&rft.issue=4&rft.spage=404&rft_id=info:doi/10.1159%2F000188510&rft_id=info%3Apmid%2F7777104&rft_id=info%3Apmid%2F7777104&rft.externalDocID=7777104
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-8151&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-8151&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-8151&client=summon